HER2 testing in gastric cancer - results of a German expert meeting

被引：2

作者：

Lordick, F. ^{[1
]}

Al-Batran, S. E. ^{[2
]}

Hofheinz, R. D. ^{[3
]}

Lorenzen, S. ^{[4
]}

Thuss-Patience, P. ^{[5
]}

Baretton, G. B. ^{[6
]}

Dietel, M. ^{[7
]}

Gaiser, T. ^{[8
]}

Kirchner, T. ^{[9
]}

Kreipe, H. H. ^{[10
]}

Quaas, A. ^{[11
]}

Roecken, C. ^{[12
]}

Rueschoff, J. ^{[13
]}

Tannapfel, A. ^{[14
]}

机构：

[1] Univ Klinikum Leipzig, Univ Krebszentrum UCCL, Liebigstr 7, D-04103 Leipzig, Germany

[2] Krankenhaus NW Frankfurt, Frankfurt, Germany

[3] Univ Med Mannheim, Mannheim, Germany

[4] Klinikums Rechts Isar, Med Klin 3, Munich, Germany

[5] Charite, CVK, Charite Ctr Tumormed CC14, Berlin, Germany

[6] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Inst Pathol, Dresden, Germany

[7] Charite, Inst Pathol, Campus Mitte, Berlin, Germany

[8] Pathol Inst Mannheim, Mannheim, Germany

[9] Univ Munich, Inst Pathol, Munich, Germany

[10] Hannover Med Sch, Inst Pathol, Hannover, Germany

[11] Uniklin Koln, Inst Pathol, Cologne, Germany

[12] Univ Kiel, Inst Pathol, Kiel, Germany

[13] Targos GmbH, Inst Pathol Nordhessen, Kassel, Germany

[14] Ruhr Univ Bochum, Inst Pathol, Georgius Agr Stiftung Ruhr, Berufsgenossenschaftlichen Univ Klinikum, Bochum, Germany

来源：

ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2016年 / 54卷 / 08期

关键词：

gastric cancer; HER2; testing; consensus; quality assurance; trastuzumab; PROGNOSTIC-FACTOR; AMPLIFICATION; ASSOCIATION; CARCINOMA;

D O I：

10.1055/s-0042-110794

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Valid HER2 testing is essential for optimal therapy of patients with HER2 positive gastric cancer and the correct use of first-line treatment. While each breast cancer is routinely being tested for the HER2 status, HER2 testing in gastric cancer has still not become part of the routine and is often only done upon request by the therapist. An interdisciplinary German expert group took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication from the perspective of pathologists and therapists. The recommendations made in this manuscript reflect the consensus of all participants and correspond to their opinions and long-term experience.

引用

页码：791 / 796

页数：6

共 50 条

[41] Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
Paula Jiménez-Fonseca
Alberto Carmona-Bayonas
Maria Luisa Sánchez Lorenzo
Javier Gallego Plazas
Ana Custodio
Raquel Hernández
Marcelo Garrido
Teresa García
Isabel Echavarría
Juana María Cano
Alberto Rodríguez Palomo
Monserrat Mangas
Ismael Macías Declara
Avinash Ramchandani
Laura Visa
Antonio Viudez
Elvira Buxó
Asunción Díaz-Serrano
Carlos López
Aitor Azkarate
Federico Longo
Eduardo Castañón
Rodrigo Sánchez Bayona
Paola Pimentel
Maria Luisa Limón
Paula Cerdá
Renata Álvarez Llosa
Raquel Serrano
Maria Pilar Felices Lobera
María Alsina
Alicia Hurtado Nuño
Carlos Gómez-Martin
Gastric Cancer, 2017, 20 : 465 - 474
[42] Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
Jimenez-Fonseca, Paula
Carmona-Bayonas, Alberto
Sanchez Lorenzo, Maria Luisa
Gallego Plazas, Javier
Custodio, Ana
Hernandez, Raquel
Garrido, Marcelo
Garcia, Teresa
Echavarria, Isabel
Maria Cano, Juana
Rodriguez Palomo, Alberto
Mangas, Monserrat
Macias Declara, Ismael
Ramchandani, Avinash
Visa, Laura
Viudez, Antonio
Buxo, Elvira
Diaz-Serrano, Asuncin
Lopez, Carlos
Azkarate, Aitor
Longo, Federico
Castanon, Eduardo
Sanchez Bayona, Rodrigo
Pimentel, Paola
Luisa Limon, Maria
Cerda, Paula
Alvarez Llosa, Renata
Serrano, Raquel
Felices Lobera, Maria Pilar
Alsina, Maria
Hurtado Nuno, Alicia
Gomez-Martin, Carlos
GASTRIC CANCER, 2017, 20 (03) : 465 - 474
[43] HER2 positive gastric cancer: Who benefits from HER2 targeted therapy?
Kolbe, K.
Haffner, I.
Schierle, K.
Maier, D.
Geier, B.
Luber, B.
Kretzschmar, A.
von Weikersthal, Fischer L.
Ahlborn, M.
Riera, J.
Rau, B.
Siegler, G.
Fuxius, S.
Decker, T.
Wittekind, C.
Lordick, F.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 156 - 157
[44] HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
Gomez-Martin, Carlos
Garralda, Elena
Jose Echarri, M.
Ballesteros, Anabel
Arcediano, Alberto
Luis Rodriguez-Peralto, Jose
Hidalgo, Manuel
Lopez-Rios, Fernando
JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (08) : 751 - 757
[45] Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
Hofmann, M.
Stoss, O.
Shi, D.
Buettner, R.
van de Vijver, M.
Kim, W.
Ochiai, A.
Rueschoff, J.
Henkel, T.
HISTOPATHOLOGY, 2008, 52 (07) : 797 - 805
[46] College of American Pathologists Guidelines for Reporting HER2 Test Results in Gastric Cancer
Whitney-Miller, Christa
Hicks, David G.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (06) : 709 - 710
[47] What are NCI-designated cancer centers using for gastric and esophageal cancer HER2 testing?
Trosman, Julia R.
Weldon, Christine B.
Tsongalis, Gregory J.
Schink, Julian C.
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[48] HER2 as a therapeutic target in the gastric cancer: is it sufficient?
Chaturvedi, Rupesh
Singh, Amar
INDIAN JOURNAL OF GASTROENTEROLOGY, 2012, 31 (03) : 103 - 105
[49] HER2 targeting therapy for advanced gastric cancer
Shitara, Kohei
ANNALS OF ONCOLOGY, 2016, 27
[50] HER2 in Resected Gastric Cancer: Is there Prognostic Value?
Fisher, Sarah B.
Fisher, Kevin E.
Squires, Malcolm H., III
Patel, Sameer H.
Kooby, David A.
El-Rayes, Bassel F.
Cardona, Kenneth
Russell, Maria C.
Staley, Charles A., III
Farris, Alton B., III
Maithel, Shishir K.
JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (02) : 61 - 66

← 1 2 3 4 5 →